key: cord-0972490-af0iwaf9
authors: Wungu, Citrawati Dyah Kencono; Khaerunnisa, Siti; Putri, Eka Arum Cahyaning; Hidayati, Hanik Badriyah; Qurnianingsih, Ema; Lukitasari, Lina; Humairah, Ira; Soetjipto,
title: Meta-analysis of cardiac markers for predictive factors on severity and mortality of COVID-19
date: 2021-03-09
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.03.008
sha: b18ac64931c08697254654e04d47af0b4fbf744e
doc_id: 972490
cord_uid: af0iwaf9

Objective Previous observational studies suggested that increased cardiac markers are commonly found in COVID-19. This study aimed to determine the relationship between several cardiac markers and the severity/mortality of COVID-19 patients. Methods We analysed several cardiac markers in this meta-analysis. RevMan 5.4 was used to provide pooled estimates for standardized mean difference (SMD) with 95% confidence intervals. Results Twenty nine clinical studies were included in this meta-analysis. This study found significantly higher CKMB (0.64, 95% CI = 0.19-1.09,), PCT (0.47, 95% CI = 0.26-0.68), NT-proBNP (1.90, 95% CI = 1.63-2.17), BNP (1.86, 95% CI = 1.63-2.09), and D-dimer (1.30, 95% CI = 0.91-1.69) in severe compared to non-severe COVID-19. This study also found significantly higher CKMB (3.84, 95% CI = 0.62-7.05), PCT (1.49, 95% CI = 0.86-2.13), NT-proBNP (4.66, 95% CI = 2.42-6.91,), BNP (1.96, 95% CI = 0.78-3.14), troponin (1.64 (95% CI = 0.83-2.45), and D-dimer (2.72, 95% CI = 2.14-3.29) in death cases compared to survived cases with COVID-19. Conclusions In conclusion, high CKMB, PCT, NT-proBNP, BNP, and D-dimer could be predictive markers for the severity of COVID-19, while high CKMB, PCT, NT-proBNP, BNP, troponin, and D-dimer could be predictive markers for the survival of COVID-19 patients.

Acute heart injury is the most commonly found cardiac abnormality in (about 8-12% of all cases). Direct myocardial injury caused by viral involvement in cardiomyocytes and systemic inflammatory effects appear to be the most common mechanisms involved in cardiac injury (Bansal, 2020) , although there are various other mechanisms, including acute myocardial infarction, myocardial supply-demand mismatch, viral myocarditis, inflammation and myocardial damage induced by oxidative stress . Troponin and natriuretic peptides [BNP (B-type natriuretic peptide) or NT-proBNP (N-terminal-pro hormone BNP)] in patients have been found to function for cardiac risk prediction and prognostic determination of severe COVID-19 patients (Mahajan et al., 2020) . The higher concentrations of CKMB, troponin, and NT-proBNP were also associated with the severity of COVID-19. Close monitoring of cardiac biomarkers is essential in reducing complications and mortality of COVID-19 (H. . Procalcitonin (PCT) is an inflammatory marker which can serve as a marker for cardiac damage as well. It has a prognostic value in acute coronary syndrome and heart failure (Ataoǧlu et al., 2010; Möckel et al., 2017) . Procalcitonin can be an indicator of disease severity and can determine the severity of COVID-19 . For about 94.44% of the COVID-19 non-survivors showed high procalcitonin levels on the day of death (Shao et al., 2020) . Another parameter that can also be a marker of the severity and mortality of COVID-19 is D-dimer . D-dimer is a marker of thrombus formation that increases in early myocardial infarction and acute coronary syndrome (Mansour and El-Sakhawy, 2020; Reihani et al., 2018) .

To obtain more convincing results, we performed a meta-analysis of cardiac biomarkers to determine the increasing levels of several cardiac markers in COVID-19 cases: CKMB, PCT, NT-proBNP, BNP, troponin, and D-dimer. The results are expected to be predictive factors of severity and mortality in patients with COVID-19.

We performed an electronic search in PubMed, Proquest, and EBSCO/CINAHL. The keywords used were: "COVID-19", "Coronavirus", "SARS-CoV-2", "Cardiac injury", "CKMB", "Creatine kinase-MB", "Procalcitonin", "PCT", "NT-proBNP", "BNP, "Brain Natriuretic Peptide", "Troponin", and "Cardiac troponin".

The electronic search was updated until August 2020. Inclusion criteria were: (1) studies involving measurement of either CKMB, PCT, BNP, NT-proBNP, D-dimer, and/or troponin in COVID-19 patients cohort studies; (2) there were data about those parameters in severe/non-severe patients or death/survived cases; (3) English language;

(4) Cohort study design; (5) include human subject; (6) Adult patients; (7) 

Heterogeneity between studies was evaluated with Q-test and I 2 test. The pool estimated SMD was measured with models based on fixed effects or random effects assumptions. If P < 0.05, it indicated heterogeneity across the studies, thus a randomeffects model was used for analysis. Otherwise, a fixed-effect model would be chosen.

The 95% confidence interval (CI) of pool estimated SMD was also calculated. Begg's funnel plot of parameter with the number of studies > 10 and Egger's test (Egger et al., 1997) for parameter with the number of studies > 2 was performed to look for evidence of publication bias. The funnel plot would be asymmetric and Egger's test would be significant (P < 0.05) once publication bias was present. Data that were not showed as mean and standard deviation were extrapolated according to Hozo et al (Hozo et al., 2005) . Review Manager version 5.4 (The Cochrane Collaboration, J o u r n a l P r e -p r o o f Oxford, UK) and JASP version 0.13.1 (University of Amsterdam) were used for this meta-analysis.

In the literature search, we initially retrieved 2,039 studies from database searching.

After deleting duplicates, 52 articles were excluded. We further reviewed the studies, and 26 of them were excluded due to non-English language. After screening the title and abstract, 1932 articles were excluded due to irrelevant study design, irrelevant topics, irrelevant population, and insufficient data or unqualified articles ( Figure 1 ). Table 1 and Table 2 . For the studies of severity, almost all included studies took place in China, mainly in Wuhan, and only 1 study took place in Switzerland. For the studies of mortality, 61.54% took place in China, 23.08% in Italy, and the rest took place in USA and Turkey. The study design of 6 of the 29 articles (20.69%) was prospective cohort, while the majority were retrospective. We checked the quality of the studies using NOQS. We found that almost all included studies had 

This meta-analysis examined the correlation between selected cardiac markers and 

In terms of publication bias evaluation, we found the studies by Zhang et al and Cen et al as the outliers. However, when we omitted the study, it did not affect the pooled analysis. The Egger's test results were significant in CKMB and PCT for severity and D-dimer for mortality groups (P = 0.021, 0.039, and 0.007, respectively). However, in the remaining groups, there was no evidence of publication bias (Table 3) . Sensitivity analysis was performed for groups containing low-quality studies onlyafter excluding them in the analysis. According to the sensitivity analysis, despite excluding studies with NOQS < 7 (high quality studies-only), the result remained stable. Besides, when we sequentially excluded one study in one turn to assess the stability of the result, no study could affect the pooled estimates. Most studies measured troponin I, except for Wang and Elena who measured troponin T. Two studies (Mikami and Violi) did not mentioned what troponin were measured. We have performed sensivity analysis for studies with troponin I only, however, the pooled result was not much different.

This meta-analysis had shown that the increase of several cardiac markers was significantly associated with COVID-19 and mortality. Cases of death due to COVID-NT-pro BNP and BNP are markers of myocardial stretch injury used for diagnosis, prevention, and safe discharge planning in heart failure (Abboud and Januzzi, 2020) .

PCT is also an indicator of myocardial damage as patients with myocardial damage have greater PCT levels than the 99th percentile of control patients (Arneth, 2008) .

Serum PCT is also a predictor of in-hospital biomarkers and 30 days of outcomes for myocardial infarction patients as well as an indicator of cardiogenic shock (Patel and George, 2016) . D-dimer is a degradation product of fibrin which indicates abnormal haemostasis and intravascular thrombosis (Johnson et al., 2019) . D-dimer levels are generally elevated in cardiac ischemia (Reihani et al., 2018) . Cytokines and host-immune dysregulation cause direct and indirect cardiac injury, leading to the increase of troponin and CKMB (Tersalvi et al., 2020) . Myocardial wall stress induced by COVID-19 causes the release of NT-proBNP and BNP. It can be worsened by renal failure as a complication which impairs their clearance (Gao et al., 2020; Sorrentino et al., 2020) . SARS-CoV2 can also cause direct cytotoxicity through J o u r n a l P r e -p r o o f 3C proteinase-mediated apoptosis, impaired host protein translation mechanisms, disbalance cellular homeostasis, and dysregulation of host immune response (Sattar et al., 2020) . Hypoxic conditions, respiratory distress, metabolic acidosis, fluid/electrolyte disturbances, and activation of the neurohormonal system can worsen heart damage, even triggering arrhythmias and cardiac arrest. (Song et al., 2020) .

Cardiac inflammation occurring in this state can increase PCT level (Unudurthi et al., 2020) . In COVID-19, there can be an imbalance between coagulation and inflammation, leading to hypercoagulopathy. There is an interaction between the innate immune system and thrombosis which can be seen from the increase in D-dimers.

patients (Colling and Kanthi, 2020) . Endothelial dysfunction, cytokine storm, Angiotensin II upregulation, and vasculitis promote coagulopathy which results in Ddimer elevation (Tersalvi et al., 2020) .

The results of this meta-analysis are in line with previous research. The meta-analysis conducted by Li et al (2020) also showed evidence of increased cardiac markers related to the severity and mortality of patients with COVID-19. The study found an increase in troponin, CKMB, myoglobin, and NT-proBNP. It was also said in the study that troponin I and NT-proBNP increased just before the death from COVID-19 occurred (Jing-wei Li et al., 2020) . A study with a large sample by Juan et al (2020) also showed that elevated troponin I, CKMB, NT pro-BNP, or myoglobin was closely associated with 28-day-all cause mortality due to COVID-19 . A longitudinal study also stated that cardiac injury is an independent marker of mortality among critically ill COVID-19 cases (C. . The previous studies mostly reported J o u r n a l P r e -p r o o f only elevated troponin as a marker of cardiac injury, for example Zou et al (Zou et al., 2020) and Aikawa et al (Aikawa et al., 2020) , while this paper have included several others cardiac markers. They also measured the outcome with Odd Ratio, which means they only include studies with categorical data (number of patients with elevated cardiac troponin in case and in control), in which not all studies had such data, thus we used mean ± SD to ensure studies showing only numerical data (mean/median) can be included. Additionally, those papers were conducted in the earlier COVID-19 pandemic, thus we provide more included studies.

Cardiac markers with the highest SMD values for predicting COVID-19 severity were NT-proBNP, followed by BNP and D-dimer (1.90, 1.86, and 1.30, respectively). For predicting mortality, cardiac markers with the highest SMD value were NT-proBNP, followed by D-dimer and BNP (4.66, 2.72, and 1.64, respectively). However, the number of included studies in NT-proBNP and BNP for both severity and mortality groups were relatively small (only two studies for each biomarker/group). Thus, we suggest D-dimer for the best predictor of severity and mortality in COVID-19, as it has many included studies (more than ten) and high significance (P < 0.00001).

In general, cardiac injury associated with COVID-19 is diagnosed from the presence of increased level of cardiac enzyme, first detected electrocardiography, or echocardiography abnormality. However, this definition varies from study to study because there is no consensus that addresses COVID-19 associated cardiac injury (Kim et al., 2020) . Early cardiac marker assessment in COVID-19 patients, especially during triage, we recommend doing so that it can prevent worsening and high mortality in COVID-19 patients.

To the best of our knowledge, this meta-analysis with 32 included different studies is the largest that evaluates the prognostic role of several cardiac markers on the severity and mortality of COVID-19 patients. However, this meta-analysis has several limitations. First, the laboratory markers were taken at baseline on admission, thus we could not predict any shift of those markers in response to therapy. Although in some cases the administration of treatment in COVID-19 patients can normalize cardiac biomarkers (Kang et al., 2020) , drug-related heart damage should be a concern in providing therapy (Zheng et al., 2020) . Levels of these biomarkers can be increased through therapy and improved oxygenation, leading to reperfusion-injury ischemia.

The release of pro-inflammatory cytokines and free radicals through this process can cause further damage to organs including the myocardium (Lin Li et al., 2020) . Some antivirals such as chloroquine and azithromycin can even cause prolongation of the QT interval, which should be taken into precautions (Kang et al., 2020) . Further clinical research is needed to determine the role of these cardiac markers as predictors of therapeutic response.

The second limitation of this study was that studies of BNP and NT-proBNP were limited in number. Another limitation was most studies did not distinguish the involvement of prior cardiovascular disease in the elevation of those biomarkers, thus it is difficult to determine whether the cardiac injury was caused by COVID-19 induction or prior cardiovascular disease. Further studies should be performed to obtain J o u r n a l P r e -p r o o f more comprehensive understandings on the mechanism of cardiac injury in COVID-

In conclusion, there were significant differences in CKMB, PCT, NT-proBNP, BNP, and D-dimer levels between severe and non-severe COVID-19 patients. We also found significant differences in CKMB, PCT, NT-proBNP, BNP, troponin, and D-dimer levels between death and survived cases. These implied that measurement of cardiac markers (CKMB, PCT, BNP, NT-proBNP, troponin, and D-dimer levels) are key laboratory parameters for diagnosis and prognosis to predict the severity and mortality of COVID-19. We suggested D-dimer for the best predictor of severity and mortality in COVID-19, as it has many included studies and high significance (P < 0.00001).

Further research is required to determine the role of more cardiac markers for predicting the prognosis of COVID-19 patients.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. 

Heart Failure Biomarkers in COVID-19

Myocardial injury characterized by elevated cardiac troponin and in-hospital mortality of COVID-19: An insight from a metaanalysis

A comprehensive appraisal of laboratory biochemistry tests as major predictors of COVID-19 severity

High-sensitivity procalcitonin (hs-PCT): A marker for identificadon of arteriosclerosis and myocardial infarction

Procalcitonin: A novel cardiac marker with prognostic value in acute coronary syndrome

Cardiovascular disease and COVID-19

Prognostic significance of cardiac injury in COVID-19 patients with and without coronary artery disease. Coron Artery Dis

COVID-19) and its implications for cardiovascular care: expert document from the

German Cardiac Society and the World Heart Federation

Laboratory predictors of death from coronavirus disease 2019 (COVID-19) in the area of Valcamonica, Italy

Clinical characteristics of Coronavirus Disease

Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019-a multi-centre observational study

Association between cytokine profiles and lung injury in COVID-19 pneumonia

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

COVID-19 and Cardiovascular Disease

COVID-19-associated coagulopathy: An exploration of mechanisms

The diagnostic and prognostic role of myocardial injury biomarkers in hospitalized patients with COVID-19

Suspected myocardial injury in patients with COVID-19: Evidence from front-line clinical observation in Wuhan, China

Predictors of mortality for patients with COVID-19 pneumonia caused by SARSCoV-2: A prospective cohort study

Correlation between the variables collected at admission and progression to severe cases during hospitalization among patients with COVID-19 in Chongqing

Bias in meta-analysis detected by a simple, graphical test

The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses 2019

Prognostic value of NT-proBNP in patients with severe COVID-19

Characteristics, predictors and outcomes among 99 patients hospitalised with COVID-19 in a tertiary care centre in Switzerland: an observational analysis

Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan

Analysis of factors affecting the prognosis of COVID-19 patients and viral shedding duration

Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: a retrospective and observational study

Estimating the mean and variance from the median, range, and the size of a sample

Procalcitonin levels in COVID-19 patients

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Elevated plasmin(Ogen) as a common risk factor for COVID-19 susceptibility

Characteristics of disease progress in patients with coronavirus disease 2019 in Wuhan

A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)

The D-dimer assay

Cardiovascular manifestations and treatment considerations in COVID-19

Updates of Cardiovascular Manifestations in COVID-19: Korean Experience to Broaden Worldwide Perspectives

A current review of COVID-19 for the cardiovascular specialist

Longitudinal correlation of biomarkers of cardiac injury, inflammation, and coagulation to outcome in hospitalized COVID-19 patients

Special Article -The impact of 2019 novel coronavirus on heart injury: A Systematic review and Meta-analysis

Clinical Characteristics and Outcomes of 74 Patients With Severe or Critical COVID-19

Changes of Laboratory Cardiac Markers and Mechanisms of Cardiac Injury in Coronavirus Disease

Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19

Early Warning Indicators of Severe COVID-19: A Single-Center Study of Cases From Shanghai

Cardiac biomarker-based risk stratification algorithm in patients with severe COVID-19

Coronavirus covid-19 has killed more people than SARS and MERS combined, despite lower case fatality rate

Initially presented acute coronary syndrome: does Ddimer imply any clinical significance?

Risk Factors for Mortality in Patients with COVID-19 in New York City

The role of procalcitonin in acute heart failure patients

Serum Procalcitonin: a Novel Biomarker in St-Segment Elevation Myocardial Infarction To Predict in-Hospital and 30 Days Outcomes

Redefining cardiac biomarkers in predicting mortality of inpatients with COVID-19. Hypertens (Dallas, Tex 1979) 2020

Diagnostic Value of D-Dimer in Acute Myocardial Infarction Among Patients With Suspected Acute Coronary Syndrome

Novel Insights Into Illness Progression and Risk Profiles for Mortality in Non-survivors of COVID-19

Association of Cardiac Injury with Mortality in Hospitalized Patients with COVID-19 in Wuhan, China

Cytokine storm induced by SARS-CoV-2 Peipei

B-Type Natriuretic Peptide as Biomarker of COVID-19 Disease Severity-A Meta-Analysis

Elevated Troponin in Patients With Coronavirus Disease 2019: Possible Mechanisms

Cardiac inflammation in COVID-19: Lessons from heart failure

Is Albumin Predictor of Mortality in COVID-19?

Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan

The timeline and risk factors of clinical progression of COVID-19 in Shenzhen

World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard

World Health Organization (WHO)

Application of ordinal logistic regression analysis to identify the determinants of illness severity of COVID-19 in China

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study

D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study

Changes of hematological and immunological parameters in COVID-19 patients

Obesity predisposes to the risk of higher mortality in young COVID-19 patients

Clinical, radiological and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID-19 patients

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China

COVID-19 and the cardiovascular system

Cardiac Injury and COVID-19: A Systematic Review and Meta-analysis

The authors declare that they have no conflict of interest.

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.